Indiaâ€™s covid-19 cases reaches all time low, Vaccine development also shows optimism
Indiaâ€™s covid-19 cases reaches low: It has been over a month that India has been witnessing a fall in the number of coronavirus cases and even now the series seems to be consistent as the covid-19 count falls 29,163 on Tuesday.Â
As per the data given by the Union Health Ministry, the tally of the coronavirus cases in India now stands at 88,74,290. There was some relief this week too as the number of active coronavirus cases remained below five lakh.Â
The death toll however was a little threatening as in a single day 449 new fatalities were reported and that pushed the whole total of the country to 1,30,519. The health ministry showed optimism that the daily number of cases have been declining for six consecutive weeks.
On Monday, India reached a historic feat with an all time low show of 30,548, asserted the health ministry. The twitter handle of the ministry took help of a graph to explain the number of cases from August to November 16. The graph clearly shows a rise till the mid of September and then there was decline in the graph.
Last peak was reached on September 17 when 97,984 coronavirus positive cases were reported. What was even more evident was the fact that covide 19 recoveries outpaced the daily infections consistently for the 44th day. The number of recovered patients stood at 43,851.
According to the Union Home Ministry, the teams involved in the process of analysing the covide situation in India were asked to submit reports to the ministry with all the specific details. It was also revealed that the centre has also devised a proper strategy to examine the spread of the virus attack in the country and especially Delhi.Â
When it comes to vaccine development, there is some hope there also. The US-based biotechnology firm Moderna Inc has shown great efficiency by totalling 94.5 percent of effectiveness criteria. The announcement has only been made after phase three trials. Earlier Pfizer and BioNTech also announced that their vaccine candidate was more than 90 percent effective.